Kelly M. George - Concepedia

Author

Kelly M. George

Procter & Gamble (United States)ORCID

Also Known As

George, K.M., George, Kelly, K George, K. GEORGE, K. George, K.M. George, Kelly George, Kelly M. George

Publications

442

Citations

H-Index

Concepts

All Affiliations

Procter & Gamble (United States)

About

Kelly M. George is an author at Procter & Gamble (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	245
2	Biochemistry	2	2	171
3	Engineering	1	1	116
4	Natural Sciences	1	1	55
5	Chemical Biology	1	1	55

Kelly M. George

Publications

411

Citations

H-Index

Page 1

	Year	Citations
Total Synthesis of (+)-Isoschizandrin Utilizing a Samarium(II) Iodide-Promoted 8-Endo Ketyl−Olefin Cyclization Gary A. Molander, Kelly M. George, Lauren G. Monovich The Journal of Organic Chemistry	2003	120
Metal Impurities Cause False Positives in High-Throughput Screening Campaigns Johannes C. Hermann, Yingsi Chen, Charles Wartchow, ACS Medicinal Chemistry Letters EngineeringHit IdentificationLead IdentificationChemistryCorrosion	2012	116
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3) Michael P. Clark, Kelly M. George, Roger G. Bookland, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineJanus Kinase 3Natural Sciences	2006	55
Neurodegenerative Disease-Related Proteins within the Epidermal Layer of the Human Skin Sigvard Åkerman, Shireen Hossain, Adeola Shobo, Journal of Alzheimer s Disease Neurodegenerative Disease-related ProteinsNeurochemical BiomarkersCytoskeletonPeptide ScienceDermatology	2019	38
Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3 Jack J. Chen, Kumar Thakur, Michael P. Clark, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineReceptor Tyrosine KinasePyrimidine-based InhibitorsPharmacology	2006	36
Identification of the first nonsense<i>CDSN</i>mutation with expression of a truncated protein causing peeling skin syndrome type B Audrey Mallet, Magdalini Kypriotou, Kelly M. George, British Journal of Dermatology	2013	31
Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence Jennifer L. S. Willoughby, Kelly M. George, Mark P. Roberto, BMC Cancer	2020	15

Page 1